BioLineRx to Report First Quarter 2014 Results on May 20, 2014
Management to hold a conference call at
The Company will host a conference call on
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will be available until
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s
Source:
Tiberend
Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com
or
Andrew
Mielach
+1-212-375-2694
amielach@tiberend.com
or
BioLineRx
Ltd.
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com